Stereotactic body radiation therapy (SBRT) use has increased dramatically in the past 15 years. SBRT is a noninvasive treatment that involves the delivery of ablative radiation doses with high precision in the course of a few treatments. Compared with traditional radiotherapy, SBRT provides better efficacy, lower toxicity, and shorter treatment duration. It has been demonstrated as an effective alternative therapy for inoperable early-stage lung cancer. It is also being increasingly used to ablate oligometastatic sites of disease progression.
While treatment of peripheral lesions has excellent outcomes for NSCLC patients and results in rare major side effects, patients are more prone to develop treatment-related toxicity after SBRT of centrally located lesions. The latter can be treated safely using adapted dose/fractionation regimes; however, research on the optimal relationship between fractionation schedules and tumor location is ongoing.
The goal of this Research Topic is to further the understanding of SBRT for NSCLC and improve outcomes for patients. We welcome submissions on, but not limited to, the following themes:
- Treatment combinations including targeted therapy and immunotherapy
- Toxicity management for SBRT for NSCLC
- Updates on fractionation schedules
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Stereotactic body radiation therapy (SBRT) use has increased dramatically in the past 15 years. SBRT is a noninvasive treatment that involves the delivery of ablative radiation doses with high precision in the course of a few treatments. Compared with traditional radiotherapy, SBRT provides better efficacy, lower toxicity, and shorter treatment duration. It has been demonstrated as an effective alternative therapy for inoperable early-stage lung cancer. It is also being increasingly used to ablate oligometastatic sites of disease progression.
While treatment of peripheral lesions has excellent outcomes for NSCLC patients and results in rare major side effects, patients are more prone to develop treatment-related toxicity after SBRT of centrally located lesions. The latter can be treated safely using adapted dose/fractionation regimes; however, research on the optimal relationship between fractionation schedules and tumor location is ongoing.
The goal of this Research Topic is to further the understanding of SBRT for NSCLC and improve outcomes for patients. We welcome submissions on, but not limited to, the following themes:
- Treatment combinations including targeted therapy and immunotherapy
- Toxicity management for SBRT for NSCLC
- Updates on fractionation schedules
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.